The global antidiabetics market size accounted for US$ 98.20 billion in 2023 and is projected to reach around USD 227.50 billion by 2033, growing at a CAGR of 8.76% from 2024 to 2033.
Key Points
- North America has held the largest revenue share of around 39% in 2023.
- Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
- By product, the insulin segment dominated the antidiabetics market with the highest share in 2023.
- By product, the drug class segment is observed to grow at a significant rate during the forecast period.
- By patient population, the geriatric segment held the dominating share of the market in 2023.
- By route of administration, the oral segment led the market in 2023. The segment is observed to sustain the position.
- By route of administration, the insulin pen/syringe segment is observed to witness the fastest rate of expansion throughout the forecast period.
Report Summary
The global antidiabetics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the antidiabetics market across the globe.
A comprehensive estimate on the antidiabetics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of antidiabetics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3914
Antidiabetics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 8.76% |
| Global Market Size in 2023 | USD 98.20 Billion |
| Global Market Size by 2033 | USD 227.50 Billion |
| U.S. Market Size in 2023 | USD 30.26 Billion |
| U.S. Market Size by 2033 | USD 70.09 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Patient Population, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized antidiabetics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: AI in Computer Vision Market Size to Attain USD 274.80 Bn by 2033
Market Players
The report includes the profiles of key antidiabetics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Recent Development
- In February 2023, IOL Chemicals and Pharmaceuticals Ltd, a leading pharmaceutical company’s share increased 12.1% and noticed the 8.25% higher at Rs 437.3 piece during the intraday session. The price of stock increased after the announcement of the antidiabetic drug ‘Metformin Hydrochloride’ approved by China’s drug supervisor.
- In February 2024, Boehringer Ingelheim launched an antidiabetic drug in India for the treatment of chronic kidney dieases getting approval from the Central Drugs Standard Control Organization (CDSCO).
- In January 2024, Glenmark Pharmaceuticals launched the antidiabetic drug a biosimilar of the Liraglutide a famous antidiabetic drug. The drug gets approval from the Drug Controller General of India (DCGI).
- In January 2022, the Danish Drug Maker, Novo Nordisk introduce the launch of anti-diabetics drug semaglutide in India for the Type 2 diabetes treatment.
Antidiabetic Market Companies
- Sanofi-Aventis
- Takeda Pharmaceuticals
- Eli Lilly
- Oramed Pharmaceuticals
- Boehringer Ingelheim
- Merck & Co. Inc.
- Novo Nordisk
- Bristol-Myers Squibb
- Halozyme Therapeutics
- Pfizer
Segments Covered in the Report
By Product
- Insulin
- Rapid Acting
- Long Acting
- Premixed Insulin
- Short Acting
- Drug Class
- Biguanides
- GLP-Agonists
- Thiazolidinediones
- Sulphonylureas
- SGLT-2
- Alpha-Glucosidase Inhibitors
- DPP-4 Inhibitors
- Meglitinides
By Patient Population
- Pediatric
- Adults
- Geriatric
By Route of Administration
- Oral
- Infusion
- Intravenous
- Insulin Pump
- Insulin Pen/Syringe
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antidiabetics Market
5.1. COVID-19 Landscape: Antidiabetics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antidiabetics Market, By Product
8.1. Antidiabetics Market Revenue and Volume, by Product, 2024-2033
8.1.1 Insulin
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Drug Class
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Antidiabetics Market, By Patient Population
9.1. Antidiabetics Market Revenue and Volume, by Patient Population, 2024-2033
9.1.1. Pediatric
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Adults
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Geriatric
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Antidiabetics Market, By Route of Administration
10.1. Antidiabetics Market Revenue and Volume, by Route of Administration, 2024-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Infusion
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Intravenous
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Insulin Pump
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
10.1.5. Insulin Pen/Syringe
10.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Antidiabetics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
Chapter 12. Company Profiles
12.1. Sanofi-Aventis
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Takeda Pharmaceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Oramed Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Boehringer Ingelheim
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck & Co. Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novo Nordisk
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Halozyme Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
